ES
CAMP icon

Enavate Sciences’s CAMP4 Therapeutics CAMP Stock Holding History

Enavate Sciences’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.66M Sell
2,190,920
-844,905
-28% -$4.01M 2.75% 7
2025
Q4 		$18.6M Sell
3,035,825
-749,977
-20% -$3.19M 3.67% 7
2025
Q3 		$11.4M Hold
3,785,802
– – 3.47% 7
2025
Q2 		$5.49M Hold
3,785,802
– – 3.11% 6
2025
Q1 		$15.1M Hold
3,785,802
– – 11.41% 4
2024
Q4 		$19.8M Buy
+3,785,802
New +$31.1M 14.19% 4

Other funds holding CAMP

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Enavate Sciences's CAMP Position: Q1 2026 in Review

Enavate Sciences reduced its CAMP4 Therapeutics (CAMP) stake by 28% in Q1 2026, selling an estimated $4.01M and leaving 2,190,920 shares worth $9.66M. The position accounts for 2.75% of the portfolio, ranked #7.

Enavate Sciences first reported a position in CAMP in Q4 2024 and has held it in 6 quarters since. The position peaked at $19.8M in Q4 2024. 46 funds tracked by Wall St. Rank hold CAMP as of Q1 2026.

  • Enavate Sciences held 2,190,920 shares of CAMP4 Therapeutics worth $9.66M as of Q1 2026.
  • Enavate Sciences sold 844,905 CAMP4 Therapeutics shares in Q1 2026, an estimated $4.01M.
  • CAMP4 Therapeutics made up 2.75% of Enavate Sciences's portfolio in Q1 2026, its #7 holding.
  • Enavate Sciences first reported a position in CAMP4 Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Enavate Sciences's CAMP4 Therapeutics position peaked at $19.8M in Q4 2024.
  • 46 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q1 2026.

Based on Enavate Sciences's 13F filing for Q1 2026, filed 15 May 2026.